share_log

Morgan Stanley Maintains Equal-Weight on Karyopharm Therapeutics, Lowers Price Target to $5

Benzinga Real-time News ·  Jan 27, 2023 10:10

Morgan Stanley analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Equal-Weight and lowers the price target from $7 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment